Business Description
Rocket Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
9IP1.Germany
•
RCKT.USA
Description
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.43 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -12.5 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year FCF Growth Rate | -13.3 | |||||
| 3-Year Book Growth Rate | 18 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.81 | |||||
| 9-Day RSI | 68.94 | |||||
| 14-Day RSI | 62.06 | |||||
| 6-1 Month Momentum % | -6.61 | |||||
| 12-1 Month Momentum % | -46.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.41 | |||||
| Quick Ratio | 13.41 | |||||
| Cash Ratio | 13.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.89 | |||||
| ROA % | -39.06 | |||||
| ROIC % | -169.63 | |||||
| ROC (Joel Greenblatt) % | -257.15 | |||||
| ROCE % | -40.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.91 | |||||
| Price-to-Tangible-Book | 3.18 | |||||
| EV-to-EBIT | -4.44 | |||||
| EV-to-Forward-EBIT | -4.51 | |||||
| EV-to-EBITDA | -4.56 | |||||
| EV-to-Forward-EBITDA | -4.58 | |||||
| EV-to-Forward-Revenue | 11.61 | |||||
| EV-to-FCF | -4.92 | |||||
| Price-to-Net-Current-Asset-Value | 4.02 | |||||
| Price-to-Net-Cash | 4.09 | |||||
| Earnings Yield (Greenblatt) % | -22.5 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RCKT
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.98 | ||
| Beta | 1.2 | ||
| Volatility % | 55.32 | ||
| 14-Day RSI | 62.06 | ||
| 14-Day ATR ($) | 1.192552 | ||
| 20-Day SMA ($) | 14.5085 | ||
| 12-1 Month Momentum % | -46.41 | ||
| 52-Week Range ($) | 7.565 - 36.87 | ||
| Shares Outstanding (Mil) | 66.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rocket Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rocket Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.